Implementation of Dienogest as a Treatment for Infertility in Women with Endometriosis
Main Article Content
Abstract
Fertility problems affect between 4 and 5 million couples each year in Mexico alone, according to data recorded by the National Institute of Statistics and Geography (INEGI). Endometriosis is a benign disorder characterized by the presence of endometrial tissue outside the uterine cavity, which are estrogen-dependent and have resistance to progesterone. The main clinical manifestations are pelvic pain, infertility and the presence of an adnexal mass. The use of transvaginal ultrasound is able to detect endometriomas >20 mm. The gold standard is diagnostic laparoscopy. One of the drugs that has begun to be used in the management of infertility in patients who are candidates for in vitro fertilization is Dienogest, which is a fourth generation progesterone agonist. Dienogest has been shown to be effective in most cases and shows potential for treating and resolving infertility associated with endometriosis and added symptoms.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
affects fertility. (2018). Retrieved 24 October 2020, from https://www.ospat.com.ar/blog/endometriosis-enfermedad-que- afecta-la- fertilidad/#:~:text=Seg %C3%BAn%20the%20World%20Organization%20of%20Women%20suffer%20from%20this% 20disease.
II. Endometriosis, an underdiagnosed disease that affects fertility. (2018). Retrieved 24 October 2020, from https://www.ospat.com.ar/blog/endometriosis-enfermedad-que- afecta-la- fertilidad/#:~:text= Seg%C3%BAn%20the%20World%20Organization%20of%20Women%20suffer%20from%20this %20disease.
III. Hoffman, B., Schorge, J., & Bradshaw, K. (2017). Williams. Gynecology (3rd ed.). Mexico City: McGraw-Hill Interamericana.
IV. Tamura, H., Yoshida, H., Kikuchi, H., Josaki, M., Mihara, Y., & Shirafuta, Y. et al. (2019). The clinical outcome of Dienogest treatment followed by in vitro fertilization and embryo transfer in infertile women with endometriosis. Journal Of Ovarian Research, 12(1). doi: 10.1186/s13048-019-0597-y.
V. Somigliana, E., Vigano, P., Benaglia, L., Busnelli, A., Berlanda, N., Vercellini, P., 2017. Management of endometriosis in the infertile patient. Semin Reprod Med. 35, 31-37.
VI. Diagnosis and treatment of endometriosis. Evidence and recommendations guide: Clinical practice guideline. Mexico, CENETEC 2012.
VII. González Gutiérrez, L., Panduro Barón, J. (2017). Gynecology (4th ed.).
VIII. History of endometriosis. Retrieved 24 October 2020, from
http://www.fertilab.net/ginecopedia/ginecologia/problemas_de_la_mujer/endometrios is/historia_de_la_endometriosis_1
IX. Laganà, A., Vitale, S., Granese, R., Palmara, V., Ban Frangež, H., & Vrtačnik-Bokal,
X. E. et al. (2017). Clinical dynamics of Dienogest for the treatment of endometriosis: from bench to bedside. Expert Opinion On Drug Metabolism & Toxicology, 13(6), 593-596.
https://doi.org/10.1080/17425255.2017.1297421
XI. Armijo, J., Mediavilla, A., Florez Beledo, J. (2013). Human pharmacology (6th ed.). Elsevier Health Sciences Spain - T.
XII. Inagaki N, Ung L, Otani T, et al: Uterine cavity matrix metalloproteinases and cytokines in patients with leiomyoma, adenomyosis or endometrial polyp. Eur J Obstet Gynecol Reprod Biol 111:197, 2003.
XIII. Pritts, E., & Taylor, R. (2003). An evidence-based evaluation of endometriosis- associated infertility. Endocrinology And Metabolism Clinics Of North America, 32(3), 653-667. https://doi.org/10.1016/s0889-8529(03)00045-8
XIV. Grandi, G., Mueller, M., Bersinger, N., Papadia, A., Nirgianakis, K., Cagnacci, A., & McKinnon, B. (2016). Progestin suppressed inflammation and cell viability of tumor
XV. necrosis factor-α-stimulated endometriotic stromal cells. American Journal Of Reproductive Immunology, 76(4), 292-298.
https://doi.org/10.1111/aji.12552.
XVI. Muller, V., Kogan, I., Yarmolinskaya, M., Niauri, D., Gzgzyan, A., & Aylamazyan,
XVII. E. (2017). Dienogest treatment after ovarian endometrioma removal in infertile women prior to IVF. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 33(sup1), 18-21. https://doi.org/10.1080/09513590.2017.1415676
XVIII. Barra, F., Laganà, A., Scala, C., Garzon, S., Ghezzi, F., & Ferrero, S. (2020). Pretreatment with dienogest in women with endometriosis undergoing IVF after a previous failed cycle. Reproductive Biomedicine Online.
doi: 10.1016/j.rbmo.2020.07.022.
XIX. Nirgianakis, K., Vaineau, C., Agliati, L., McKinnon, B., Gasparri, M., & Mueller, M. (2020). Risk factors for non-response and discontinuation of Dienogest in endometriosis patients: A cohort study. Acta Obstetricia Et Gynecologica Scandinavica. doi: 10.1111/aogs.13969.
XX. Becker CM, Gattrell WT, Gude K, Singh SS. Reevaluating response and failure of medical treatment of endometriosis: a systematic review. Fertil Steril. 2017;108:125- 136